The recommended dose of toripalimab is usually 3 mg per kg of body weight, administered once every 2 weeks. The exact number of vials per dose is calculated based on the patient’s body weight and the drug specification.
For example, if a patient weighs 60 kg and the drug is supplied as 240 mg/vial, 1 vial is needed per dose (60 kg × 3 mg/kg = 180 mg, which is covered by one 240 mg vial). In clinical practice, the dosage must be strictly followed as prescribed by a doctor; no self-adjustment is permitted.
Dosage Calculation
Dosing is weight-based (3 mg/kg), given via intravenous infusion once every 2 weeks. Examples:
Body weight 50 kg: 50 × 3 = 150 mg. If the specification is 240 mg/vial, 1 vial is used (remaining dose to be discarded per medical protocols).
Body weight 70 kg: 70 × 3 = 210 mg, also requiring 1 vial.
Differences in Drug Specifications
Different strengths (e.g., 80 mg/vial, 240 mg/vial) affect the number of vials used. The exact specification must be confirmed per prescription, with dispensing guided by a physician or pharmacist.
Individualized Dosage Adjustment
Some patients may require dose modification or treatment interruption due to abnormal liver function, adverse reactions (e.g., immune-related pneumonia, colitis), or combination therapy regimens. Such decisions must be evaluated and determined by a doctor.
Administration and Precautions
For intravenous infusion only, to be administered by healthcare professionals; self-injection is prohibited.
Complete baseline tests (e.g., blood routine, liver and kidney function) are required before treatment, and immune-related adverse events must be monitored regularly during therapy.
Common side effects include fatigue, rash, pruritus, etc. Seek immediate medical care if severe reactions occur (e.g., dyspnea, persistent diarrhea).
Prescription and Medical Guidance
Toripalimab is a prescription medication. Before use, it must be evaluated by an oncologist for approved indications (e.g., melanoma, nasopharyngeal carcinoma), and contraindications (e.g., active autoimmune diseases) must be excluded.
During treatment, follow up as instructed by your doctor, report adverse reactions promptly, and do not discontinue or modify the regimen without medical approval.
